Christopher Arthur

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour et al. · Blood · 2013 · 706 citations

Medicine, Immunology, Pharmacotherapy +11

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

David M. Ross, Susan Branford, John F. Seymour et al. · Leukemia · 2010 · 267 citations

Medicine, Molecular Biology, Oncology +15

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Jörge E. Cortes, Jane F. Apperley, Elza Lomaia et al. · Blood · 2021 · 193 citations · Full text

Medicine, Oncology, Pharmacology +6

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

Ashwin Unnikrishnan, Elli Papaemmanuil, Dominik Beck et al. · Cell Reports · 2017 · 130 citations · Full text

Medicine, Hematology, Oncology +16